Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method

Norman Fry, John Duncan, L. Vaghji, Robert George, Timothy Harrison

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

Reports of the development of antimicrobial resistance by Bordetella pertussis to macrolides in the United States and Taiwan, together with a recent increase in pertussis notifications and laboratory-confirmed cases in England and Wales in 2008, prompted the examination of historical and recent clinical isolates from patients for evidence of such resistance in our collection. Isolates submitted to our laboratory as part of the enhanced surveillance scheme for pertussis, from 2001 to 2009, were tested against three agents, erythromycin, clarithromycin and azithromycin, by the Etest (bioMérieux) method. All isolates (n = 583) were fully susceptible to all three agents tested (minimum inhibitory concentrations [MICs] ≤0.125 μg/ml). All but one strain (582/583) had MICs of ≤0.064 for all three agents. The control strain of B. pertussis A228 (from the Centers for Disease Control and Prevention [CDC], Atlanta, Georgia, USA) with a resistant phenotype had an MIC of >256 μg/ml. Although no evidence of resistance was found in the strains tested from the United Kingdom, screening for antimicrobial resistance of B. pertussis may be warranted in cases that are unresponsive to macrolide treatment and to provide early warning of such emergence in the future.

Original languageEnglish
Pages (from-to)1183-1185
Number of pages3
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume29
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method'. Together they form a unique fingerprint.

Cite this